Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Surveillance System Evaluation for COVID-19 Vaccine–Associated Adverse Events Following Immunization (AEFI), Sindh Pakistan (2021) (Preprint)

View through CrossRef
BACKGROUND In February 2021, a mass vaccination campaign commenced in Sindh Province in response to the COVID-19 epidemic. An adverse-events-following-immunization surveillance system (AEFI-SS) was established to monitor the adverse events following vaccination. OBJECTIVE We evaluated the AEFI-SS with the aim to identify its strengths and weaknesses and suggest recommendations. METHODS In May-June 2021, a descriptive evaluation study was conducted in Sindh Province, Pakistan. The Centers for Disease Control and Prevention’s (CDC) updated guidelines for evaluation of SS-2001 were followed to measure the qualitative, quantitative, and utility attributes of the AEFI-SS. Key stakeholders were identified based on their involvement in the AEFI-SS and were interviewed. Case investigation proformas for the AEFI were randomly reviewed for data quality, timeliness, and completeness. Sensitivity was calculated. Each attribute was rated as good, fair, or poor based on a scoring legend. RESULTS The SS was useful in effectively identifying 7147 cases of AEFIs. Timeliness of all AEFI cases was good and was found to be 100%, as all cases were reported within 24 hours. The World Health Organization (WHO)-approved case definition was used for the identification of AEFI cases and had a simple flow of information. The AEFI-SS was good in data quality and completeness (100%), and data collection tools were filled by trained medical officers. Sensitivity was 100%, and the predictive value positive (PVP) was not calculated due to the absence of a laboratory component. Good representativeness (>80%) of the population was covered by 1004 vaccination centers. The system was found to be stable as resources of the health department government of Sindh were being used. The AEFI-SS was paper based and deficient in a feedback mechanism. CONCLUSIONS Sindh Province has an appropriate surveillance mechanism for AEFI detection and management for the ongoing COVID-19 vaccination SS. The representativeness can be increased by involvement of the private health sector. Establishment of a feedback mechanism and digital data transformation and integration of the AEFI system with the Expanded Program on Immunization (EPI) are recommended.
Title: Surveillance System Evaluation for COVID-19 Vaccine–Associated Adverse Events Following Immunization (AEFI), Sindh Pakistan (2021) (Preprint)
Description:
BACKGROUND In February 2021, a mass vaccination campaign commenced in Sindh Province in response to the COVID-19 epidemic.
An adverse-events-following-immunization surveillance system (AEFI-SS) was established to monitor the adverse events following vaccination.
OBJECTIVE We evaluated the AEFI-SS with the aim to identify its strengths and weaknesses and suggest recommendations.
METHODS In May-June 2021, a descriptive evaluation study was conducted in Sindh Province, Pakistan.
The Centers for Disease Control and Prevention’s (CDC) updated guidelines for evaluation of SS-2001 were followed to measure the qualitative, quantitative, and utility attributes of the AEFI-SS.
Key stakeholders were identified based on their involvement in the AEFI-SS and were interviewed.
Case investigation proformas for the AEFI were randomly reviewed for data quality, timeliness, and completeness.
Sensitivity was calculated.
Each attribute was rated as good, fair, or poor based on a scoring legend.
RESULTS The SS was useful in effectively identifying 7147 cases of AEFIs.
Timeliness of all AEFI cases was good and was found to be 100%, as all cases were reported within 24 hours.
The World Health Organization (WHO)-approved case definition was used for the identification of AEFI cases and had a simple flow of information.
The AEFI-SS was good in data quality and completeness (100%), and data collection tools were filled by trained medical officers.
Sensitivity was 100%, and the predictive value positive (PVP) was not calculated due to the absence of a laboratory component.
Good representativeness (>80%) of the population was covered by 1004 vaccination centers.
The system was found to be stable as resources of the health department government of Sindh were being used.
The AEFI-SS was paper based and deficient in a feedback mechanism.
CONCLUSIONS Sindh Province has an appropriate surveillance mechanism for AEFI detection and management for the ongoing COVID-19 vaccination SS.
The representativeness can be increased by involvement of the private health sector.
Establishment of a feedback mechanism and digital data transformation and integration of the AEFI system with the Expanded Program on Immunization (EPI) are recommended.

Related Results

Adverse Events Following Immunization (AEFI) Reporting in Urban and Rural Bangladesh
Adverse Events Following Immunization (AEFI) Reporting in Urban and Rural Bangladesh
Complete reporting and management of adverse events following immunization (AEFIs) helps maintain the quality of vaccine delivery and monitor vaccine safety. We assessed AEFI repor...
Adverse Events Following Immunization (AEFI) of COVID-19 Vaccine: A Descriptive Survey in Malang City
Adverse Events Following Immunization (AEFI) of COVID-19 Vaccine: A Descriptive Survey in Malang City
Vaccination is used to stop the transmission of COVID-19. However, it can stimulate Adverse Event Following Immunization (AEFI) symptoms, ranging from mild to severe. This study ai...
Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand
Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand
Background: Myocarditis and pericarditis cases following Coronavirus 2019 (COVID-19) vaccination were reported worldwide. In Thailand, COVID-19 vaccines were approved for emergency...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...

Back to Top